Cancer is one of the leading causes of death in the industrial world. Despite our advancing knowledge of cancer, there is still a need for additional information for management of the disease. Improvement to patient care can be expected if clinicians have more information on  prognosis, early indications of treatment response, and disease progression. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data.

IDL Biotech offers a panel of in vitro diagnostic tumor activity markers for use in the most common types of cancer, including breast, colorectal, lung, ovarian and prostate cancer. IDL tumor markers offer enhanced sensitivity and lead times. Our tests provide clinicians with greater insight into disease status to improve cancer patient management.

IDL assays are available in different formats, including enzymatic (ELISA) assay, radiometric (IRMA) assay, and point-of-care (POC) test.

Measuring Tumor Activity Provides Added Benefits

Tumor markers are simple, non-invasive, and sensitive diagnostic tools. Today, many clinical decisions are made based on the use of tumor markers that measure tumor burden or volume. An important complement to that information is how active those tumor cells are. Knowing cell activity provides a much more complete picture of disease status, progression and treatment efficacy.

All IDL tumor marker assays are designed to measure tumor cell activity through the detection of soluble fragments of cytokeratins, the intermediate filament proteins that contribute to the mechanical integrity of the epithelial cells. The benefit of determining cytokeratin levels in the body lies both in early detection of cancer recurrence, and in the early assessment of therapy response.

IDL tumor markers also predict tumor progression for several cancer types with a long lead time.